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Edited by Horst FeldmannAbstract The pluripotent nature of human embryonic stem cells
(hESC) has attracted great interest in using them as a source of
cells or tissue in cell therapy. However, in order to be used in
regenerative medicine, the pluripotent hESC lines should be
established and propagated according to good manufacturing
practice quality requirements. The cultures should be animal sub-
stance free in order to exclude the risk of infections and immu-
nogenity. They should also be genetically and epigenetically
normal. The detailed molecular mechanisms of their pluripotency
are still not deﬁned. Using human feeder cells, a medium contain-
ing only human proteins, the mechanical isolation of the inner
cell mass and mechanical passaging of hESC, is a safe option
until a functional deﬁned medium containing physiological con-
centrations of regulatory factors is available.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Human embryonic stem cell lines (hESC) can be derived
from the inner cell mass (ICM) of preimplantation poor qual-
ity blastocysts, obtained from in vitro fertilization (IVF)
treatment, which have been donated for research and which
would otherwise be discarded. Since the establishment of ﬁrst
hESC lines in 1998 [1], research has progressed rapidly and
several studies have described the derivation and culture of
new hESC lines. A high quality hESC line expresses speciﬁc
cell surface markers (SSEA-4, TRA-1–60, TRA-1–81) and
transcription factors (Oct-4 and Nanog), is karyotypically
normal and has high telomerase and alkaline phosphatase
enzyme activities [1]. Human ESCs are able to grow and
self-renew unlimitedly, they can be propagated in culture
for extended periods and have an ability to diﬀerentiate toAbbreviations: hESC, human embryonic stem cells; GMP, good ma-
nufacturing practice; ICM, inner cell mass; FBS, fetal calf serum; SR,
serum replacement; ECM, extracellular matrix; IVF, in vitro fertiliza-
tion
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layers; ectoderm, mesoderm and endoderm. Their diﬀerentia-
tion potential has raised hope that these cells could be a renew-
able source for cell transplantation in severe degenerative
diseases [2].
In order to enable the use hESC in cell transplantation in
human, it is necessary to eliminate the risk of infection trans-
mitted by retroviruses and other animal pathogens, and immu-
noreactions caused by animal substances in cell cultures [3].
Therefore, animal material free derivation methods, animal-
free culture media and human feeder cells or animal-free sub-
strate as coating material in the hESC culture systems should
be established.2. Culture of hESC on feeder cells
2.1. First cultures on mouse-derived feeder cells
Human ESC lines were originally derived and propagated
using mouse fetal ﬁbroblasts as feeder cells, similar to those
used in derivation of mouse ESC lines [1,4]. The culture med-
ium also contained fetal bovine serum (FBS). These animal
substance containing systems bear the subsequent risk of con-
tamination with retroviruses and other pathogens, which could
be transmitted to patients. It has also been shown that the
hESC cultured under such conditions contain non-human
sialoproteins, which are immunogenic to humans [3].
2.2. Cultures on human feeder cells
Next, human fetal muscle and skin and adult fallopian tube
cells were used for the culture of existing hESC lines, and hu-
man serum was successfully used in the propagation of one line
[5]. We have derived new hESC lines using human foreskin
ﬁbroblast as feeder cells [6], and since then we have derived
25 hESC lines on such feeder cells. Amit et al. [7] used such
cells for the maintenance of an existing hESC line. Other hu-
man feeder cells used for derivation of new hESC have been
human placental ﬁbroblasts [8,9], human endometrial cells
[10], adult marrow stroma cells [11] and hESC-derived ﬁbro-
blasts [12]. For the maintenance of existing lines, human feeder
cells have been used by several teams (Table 1). In addition,
adult skin and muscle cell could support maintenance of hESC
[13]. None of these culture systems was animal substance free
because almost all had used FBS in the establishment of the
feeder cells and immunosurgery had been used in most isola-
tions of the ICM (Table 1).blished by Elsevier B.V. All rights reserved.
Table 1
Recently established derivation and culture methods for human embryonic stem cells using human feeder cells or feeder-free conditions
Substrate/feeder-cell type Feeder-cell medium
components





Human foreskin FBS/HS SR, bFGF M – [7]
FBS FBS, LIF D/M Pro/ISR [6]
FBS SR, bFGF D/M Pro/ISR [24]
Placenta FBS SR, bFGF D/M Tyr/Mech [8]
Uterine endometrium FBS SR, bFGF D/M Pro/ISR [10]
Adult marrow stroma FBS SR, bFGF M – [11]
hESC derived FBS SR, bFGF M – [25]
ﬁbroblasts FBS SR, bFGF M – [26]
HS/FBS SR, bFGF D/M Pro/Mech [12]
Fetal muscle HS FBS or HS D/M Pro/ISR [5]
Fetal skin D/M
Adult fallopian tube D/M
Adult skin
Adult muscle HS/FBS FBS or M – [13]a
SR, bFGF M
Matrigel – CM (MEFs), SR, bFGF M – [14]
Matrigel – CM (hESC-dF), SR , bFGF M – [25]
Matrigel – SR, bFGF, GSK3 inhibitor M – [27]
Matrigel – SR, bFGF + noggin or high bFGF M [28]
Matrigel – SR, noggin, high bFGF M – [29]
Matrigel – CM(MEFs/HES)S1P, PDGF, bFGF M – [30]
Matrigel/laminin – X-vivo 10, high bFGF M – [23]
Matrigel – Deﬁned, animal-free medium, bFGF,
LiCl, GABA, pipecolic acid, TGFb
D/M Pro/ISR [18]
FBS-coating – CDM, activin A, noudal, bFGF M – [31]
ECM from MEFs – SR, Plasmanate, bFGF D/M Pro/ISR [17]
Laminin – SR, activin A, KGF, NIC M – [15]
Fibronectin – CM, SR, bFGF – [32]
Fibronectin – SR, TGFb, LIF, bFGF M – [16]
HS matrix – CM (hESCd-F) M – [33]
Laminin – X-vivo10, high bFGF M – [8]
Abbreviations: FBS, fetal bovine serum; HS, human serum; SR, serum replacement; bFGF, basic ﬁbroblast growth factor; LIF, leukaemia inhibitor
factors; Pro, pronase used for removal of zona; ISR, immunosurgery for removal of trophoectoderm cells; Tyr, Tyrode’s acid used for removal of
zona; Mech, mechanical removal of trophoectodermal cells; CM, conditioned medium; MEFs, mouse embryonic ﬁbroblasts; hESC-dF, human
embryonic stem cell derived ﬁbroblasts; GSK3 inhibitor, glycogen synthase kinase-3 inhibitor; HES, human embryonic stem cell; S1P, sphingosine-1-
phosphate; PDGF, platelet derived growth factor; LiCl, lithidium chloride; GABA, c-aminobutyric acid; TGFb, transforming growth factor beta;
CDM, chemically deﬁned medium; KGF, keratinocyte growth factor; NIC, nicotinamide.
aIn this work 11 diﬀerent type of human cells as feeder cells were tested.
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3.1. Cultures on extracellular matrix
The ﬁrst feeder-free maintenance systems for existing hESC
were cultures on Matrigel [14]. Matrigel is manufactured from
mouse material and is composed of several extracellular matrix
(ECM) components, and it contains several growth factors. A
conditioned medium from fetal mouse ﬁbroblasts allowed a
non-diﬀerentiated growth of existing hESC lines on Matrigel
[14] (Table 1). A non-diﬀerentiated growth up to 10 passages
was reported. For possible use in human cell transplantation,
such hESC are very sub-optimal. The following improvements
were laminin [15] and ﬁbronectin [16] as ECMs. Either condi-
tioned medium from mouse ﬁbroblasts, or combinations of
growth factors (bFGF, TGFb, activin A, Nodal, Noggin,
LIF, PDGF) were used (Table 1). The diﬀerentiation on the
edges of the colonies can be seen in many of these reports.
3.2. Feeder-free derivation
A feeder-free derivation of hESC has also been possible.
ECM form mouse fetal ﬁbroblasts was used in the ﬁrst success-ful feeder-free derivation [17]. Such ECM is not suitable for of
human cell transplantation. Matrigel was used as ECM in the
ﬁrst study describing chemically deﬁned derivation of two
hESC lines [18], making this system also sub-optimal regarding
cell transplantation. One of these lines had karyotype 47XXY,
which is common in human embryos. The second gained an
extra chromosome 12 at passage level 40. Chromosomal
abnormalities have been described in hESC lines earlier
[19,20]. It is suspected that culturing these cells in two diﬃcult
conditions may promote chromosomal aberrations [19]. It may
be that a feeder-free derivation and culture may not be optimal
culture systems for transplantable cells, either, before the
molecular mechanisms of self-renewal are fully known.4. Culture medium for hESC, serum and serum replacement
FBS was ﬁrst used in the culture medium (Table 1). It was
soon replaced by serum replacement [21,22]. The widely used
serum replacement (SR) (Invitrogen) promoted well the non-
diﬀerentiated growth [23], but it still contained animal pro-
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replacements has been reported [8,24] (Table 1). All these sys-
tems contained at least some component which was not animal
substance free, immunosurgery being the usual one (Table 1).5. Good manufacturing practice
GMP is a clearly deﬁned quality system, which is presented
in an EU commission directive 2003/94/EC, of October 2003.
According to the new EU directive (2004/23/EC), the hESC
for transplantation have to be cultured in GMP conditions
to guarantee the safety and quality of the cells. The principles
and guidelines enable the manufacturers to eliminate or mini-
mise the instances of contamination, mixups and errors. They
protect the consumer from using products, which are not eﬀec-
tive or are even dangerous. The GMP regulations address re-
cord keeping, personnel qualiﬁcation, sanitation, cleanliness,
equipment veriﬁcation, the validation of the processes, and
complaint handling.
The identiﬁcation of all derivation and culture consumables
meeting GMP standards is an important challenge for those
deriving new hESC lines. The directive also sets out quality
requirements for the IVF laboratories which improve the qual-
ity of the discarded embryos by eliminating the risks during the
IVF procedure and embryo storage.6. A safe option: GMP quality cultures on human feeder cells
with no animal-derived constituents
As a result of this review, we might construct a safe, micro-
biologically, chromosomally, epigenetically and immunologi-
cally normal culture system for hESC. It would be a feeder
cell based culture with human skin ﬁbroblasts derived using
human serum in a GMP facility. The derivation of the hESC
should also take place in a GMP facility. The GMP quality
culture medium should only consist of human proteins. In or-
der to establish GMP quality and animal-free culture method,
we have derived new hESC lines using human foreskin ﬁbro-
blast as feeder cells [6], and we have since then derived 25
hESC lines on such feeder cells using serum replacement [24].
We have also established method to derive new human skin
ﬁbroblasts under GMP facilities using human serum contain-
ing medium. In parallel, we are testing new culture medium
components to replace currently used SR in the derivation
and cultures of hESC. So far, the culture condition with feeder
cells seem to be most feasible since a conditioned medium from
human foreskin ﬁbroblast feeder cells does not seem to support
undiﬀerentiated growth of hESC (Stro¨m et al., submitted).
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